Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics to Present at Upcoming September Investor Conferences
06:30am, Wednesday, 06'th Sep 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why
03:02pm, Friday, 01'st Sep 2023
The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.
Sage Therapeutics to lay off 40% of staff after FDA rejects Zurzuvae for 'major depressive disorder'
10:27am, Thursday, 31'st Aug 2023
SAGE Therapeutics (NASDAQ:SAGE) has announced a major reorganization, including laying off about 40% of its workforce, after the US Food & Drug Administration rejected its drug application for major d
Sage Therapeutics to cut 40% of jobs after depression drug setback
06:44am, Thursday, 31'st Aug 2023
Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
05:10am, Thursday, 24'th Aug 2023
The Food and Drug Administration only granted partial approval to zuranolone this month. Sage is an unprofitable business, so it's a big blow that ensures the company's operations remain in the red fo
Why Shares of Sage Therapeutics Slumped This Week
11:23am, Friday, 11'th Aug 2023
The FDA approved Zurzuvae for postpartum depression but not for major depressive disorder. Sage saw revenues and net losses climb in the second quarter.
2 Beaten-Down Stocks That Still Aren't Worth Buying
08:50am, Friday, 11'th Aug 2023
Novavax's prospects in the coronavirus vaccine market look dim. Sage Therapeutics' recent regulatory news was a major blow to its prospects.
Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug
04:15pm, Monday, 07'th Aug 2023
Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder.
2 Biotech Stocks Staging Large Swings
02:32pm, Monday, 07'th Aug 2023
Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69.
Sage Therapeutics, Inc. (SAGE) Business Update Call (Transcript)
01:21pm, Monday, 07'th Aug 2023
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Business Update Call August 8, 2023 8:00 PM ET Company Participants Ashley Kaplowitz - Investor Relations Barry Greene - Chief Executive Officer Laura Gault - Ch
Why Sage Therapeutics Stock Is Crashing Today
11:44am, Monday, 07'th Aug 2023
The U.S. FDA didn't approve zuranolone in treating major depressive disorder. However, the FDA did approve the drug in treating postpartum depression.
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug
10:52am, Monday, 07'th Aug 2023
The FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.
Why Is Sage Therapeutics (SAGE) Stock Down 48% Today?
09:31am, Monday, 07'th Aug 2023
Sage Therapeutics (NASDAQ: SAGE ) stock isn't doing the best on Monday after the FDA weighed in on the biopharmaceutical company's depression drug zuranolone. According to Sage Therapeutics, it's unha
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
09:20am, Monday, 07'th Aug 2023
Sage stock plummeted Monday after the FDA approved its drug, Zurzuvae, in postpartum depression, but not major depressive disorder.
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
09:08am, Monday, 07'th Aug 2023
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $2.68 per share versus the Zacks Consensus Estimate of a loss of $2.53. This compares to loss of $2.13 per share a year ago.
